• Establish Research and Early Development (RED) team at AbbVie Computational Oncology• Set strategies for science and operation; Define Bioinformatics guidelines for program transition milestones within oncology portfolio• Establish outsourcing model and manage external Bioinformatics CROs • Program functional lead for AbbVie SEZ6 franchise

• Lead communications team for AbbVie Genomics Research Center• Design and execute communications strategies

• Oversee genomic efforts in discovery and clinical development for AbbVie tumor targeting programs (Antibody-Drug Conjugates, CD3 bispecifics, NK cell engager, soluble TCR and cell therapies)• Executive member in governance committee driving discovery and early development programs • Functional lead for discovery and clinical development under tumor targeting programs• Designated functional lead for Companion Diagnostics (CDx) across diseases• Lead molecular characterization and biology strategies on AbbVie patient-derived xenograft (PDX) bank• Core member in novel discovery initiative through in vivo genetic screen, 3D organoids, single cell platforms• Lead reverse translational initiative and Real World Evidence initiative for biomarker strategies on drug response and combination • Build in-house data solution for visualization and integration • Establish immune repertoire sequencing platform for antibody discovery• Support publications and regulatory submissions

Bioinformatics lead for breast, ovarian and lung cancer discovery programs at AbbVie South San Francisco site. Translational biomarker lead for clinical development under ABBV-011, Cofetuzumab pelidotin and Rovalpituzumab Tesirine. Design and execute single-cell sequencing studies for tumor heterogeneity and cancer stem cell population characterization. Support IND filing.

Bioinformatics lead for both pre-clinical and clinical studies across all oncology programs at AbbVie StemCentrx. Mining on internal and external high-throughput genomic data for target/linker identification and optimizing tissue specificity for ADC platform; understanding mechanisms of action; biomarker identification for drug sensitivity and resistance. Supervise junior scientists.

Led and supported genomic studies for clinical development of Andecaliximab, Momelotinib, Filgotinib, GS-4875, Entospletinib, focusing on oncology and IBD programs. Contributed to End of Phase 1 package for Andecaliximab UC trial FDA submission. • Identify PD markers using genomic DNA and RNA sequencing data from clinical specimens. • Identify molecular signatures underlying drug resistance.• Study responsiveness for checkpoint inhibition at molecular level• In depth characterization of TiLs in bulk tumor through in-silico cell type deconvolution. • Liquid biopsy platforms evaluation; nominated indication specific ctDNA biomarker panel for internal clinical trials.

• Method development for breast cancer molecular subtype classification • Investigating tumor-host interactome in clinical samples to nominate potential drug targets from tumor microenvironment.

• Machine learning approaches & Statistical modeling in high-throughput molecular data• Personalized medicine for breast cancer management through genomic profiling: • Clinical relevant biomarker discovery • Gene-signature based survival risk prediction • Network biology in pathogenesis and cancer progression

Investigate breast cancer progression by integrative pathway analysis combining various high-throughput genomic data (expression, aCGH, mutation)